clinical trial · NCT07003984
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
Bavarian Nordic·phase3·recruiting·n = 720
Chikungunya VirusCHIKV VLP vaccinePlacebo
brief summary
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.
started
Jun 5, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Mar 24, 2026
official title
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol